Considering the above, the findings of this study, which analyzed 2,726 patients with infectious diseases, are highly significant in that they reveal changes in complement markers that can be used clinically.
← all excerpts
Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis of health insurance claims in Japan.
1
—
—